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Abstract 
Cytosine arabinoside (ara-C) is a component of many protocols for the treatment of 
acute leukaemia and non-Hodgkin lymphomas in humans. Aim of the study was to 
prospectively evaluate the efficacy of ara-C in a myeloablative regimen in a cohort of 
canine lymphomas with bone marrow involvement. Seventeen dogs were enrolled. 
Eight were treated with a VCAA-based protocol (Group 1) and 9 with the same regimen 
added with ara-C (Group 2). Ara-C was administered on a 5-day schedule as an 
intravenous continuous infusion at the dose of 150 mg m-2 per day for 5 consecutive 
days. During treatment complete remission (CR) was achieved in 2 dogs in Group 1 and 
in 8 dogs in Group 2. CR rate was significantly higher in Group 2 (p < 0.01). Median 
survival was 72.5 days (range, 6 to 174) in Group 1 and 243 days (range, 73 to 635) in 
Group 2. Survival was significantly longer in Group 2 (p < 0.001). Both protocols were 
well tolerated, with a low incidence of adverse events. Ara-C added to a VCAA-based 
protocol appears to be safe and beneficial in dogs with stage V lymphoma. 
Incorporation of the nucleoside analogue might be crucial for the development of future 
therapeutic strategies in dogs. 
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Introduction 
The prognosis of canine lymphoma (LSA) with bone marrow (BM) involvement (stage 
V) is usually worse than that of LSA of different clinical stages, with shorter median 
survival times in the first case.1-6 The marrow infiltration itself plays a major adverse 
prognostic role, since traditional chemotherapeutic regimens, such as COAP-based 
protocols, have not usually proven effective to wipe out neoplastic cells infiltrating the 
BM. Of concern, chemotherapy is frequently complicated by systemic toxicity and 
severe myelosuppression, and these adverse effects are more pronounced in the 
presence of marrow failure, leading to treatment delays and to drug dosage reductions, 
thereby reducing dose intensity and possibly affecting clinical outcome.1,7 Treatment of 
stage V canine LSA with conventional chemotherapy is usually frustrating and 
associated with low probability of response and short duration of remission.1-6 Thereby, 
alternative and more efficacious protocols are needed to improve outcome. 
Nucleoside analogues were first introduced in the 1960s, and since then further progress 
has made these drugs into one of the most efficacious agents for the treatment of human 
hematopoietic malignancies. Cytosine arabinoside (cytarabine; ara-C) is a cell-cycle S-
phase-specific agent that inhibits the DNA polymerase, and is classified as an 
antimetabolite.8 Ara-C is a prodrug, thereby requiring phosphorylation to triphosphate 
to elicit cytotoxicity. Because of its short plasmatic half-life, ara-C has to be given as 
multiple intravenous (IV) injections or as a continuous IV infusion in order to be 
efficacious against cells passing from G1 to S-phase.8 In people, ara-C is most 
extensively used as first-line agent in the treatment of acute myeloblastic leukaemia, 
acute lymphoblastic leukaemia, meningeal leukaemia and relapsed non-Hodgkin LSA.9-
12
In dogs, ara-C is not widely used and little information has been published in the 
scientific literature. This agent is mainly of use against canine LSA, either in the 
induction of remission,13 or as rescue agent incorporated in the DMAC protocol,14 or 
intrathecally in the case of central nervous system involvement.15 Ara-C has been also 
used to treat one dog with acute myelomonocytic leukaemia16 and several dogs with 
meningoencephalitis.17 To our knowledge, there are no studies on the use of ara-C to 
specifically treat stage V (BM infiltration) canine LSA.  
Aim of this study was to prospectively evaluate the clinical outcome of dogs affected by 
LSA with BM involvement treated with a modified VCAA chemotherapeutic regimen, 
with or without the addition of IV ara-C. Evaluated clinical endpoints for all dogs 
included remission rate and survival time. We hypothesized that the incorporation of 
ara-C would show a survival advantage over traditional VCAA-based protocols in LSA 
dogs with BM involvement. 
 
 
MATERIALS AND METHODS 
Eligibility 
Dogs with newly-diagnosed, previously untreated LSA with BM infiltration (stage V 
based on the World Health Organization system for canine LSA)18 were eligible for 
recruitment. Staging procedure included history and physical examination, complete 
blood cell count (CBC) with differential, serum biochemistry profile, urinalysis, 
cytological evaluation of peripheral lymph nodes, thoracic radiographs, abdominal 
ultrasound, cytological ultrasound-guided evaluation of liver and spleen, and cytological 
evaluation of BM. Immunophenotyping by flow cytometry was performed on lymph 
node aspirate, peripheral blood and BM. A panel of antibodies, including CD18, CD45, 
CD3, CD4, CD8, CD21, CD34, sIgG, sIgM and CD79a were used for cellular labelling. 
Dogs were enrolled irrespectively of immunophenotype. For the diagnosis of BM 
involvement to be made with confidence, lymphoid blast cells had to represent over 
20% of all nucleated cells. Distinction between LSA and acute lymphoblastic leukaemia 
can be challenging by the sole clinical and morphological evaluation, and 
immunophenotyping by labelling cells with CD34 is believed to have diagnostic 
value.19 In fact, leukaemia cells are usually CD34 positive, express common antigens at 
low extent and lack some antigens characteristic of mature cells, such as CD21, sIgG 
and sIgM, whereas LSA cells are usually CD34 negative20 and express common 
antigens at a higher intensity21 as well as CD21 and surface immunoglobulins (in B 
lymphomas).22 To be enrolled in this study, dogs had to show lack of CD34 expression 
on neoplastic cells, thus confirming the diagnosis of LSA rather than leukaemia. 
The following exclusion criteria were applied: prior therapy with any cytotoxic 
chemotherapeutic drug and/or steroids, serious non-malignant disease, concomitant 
malignancies, and any heart condition precluding the use of doxorubicin. 
Owners decided whether to add ara-C to the conventional chemotherapeutic protocol. 
Dogs whose owners rejected to incorporate ara-C were included in Group 1, whereas 
dogs whose owners wished to add ara-C were included in Group 2. A written informed 
consent was obtained from all owners. 
 
Chemotherapeutic designs 
Group 1 
Dogs included in Group 1 were treated in an outpatient setting and underwent a 
sequential 4-weeks poly-chemotherapeutic protocol (modified VCAA) for canine LSA, 
as previously reported,23 as follows: subcutaneous 400 UI kg-1 L-Asparaginase 
(Leunase, 10000 UI, Rhône- Poulenc Rorer, Rouen, France) on day 1, followed by IV 
0.75 mg m-2 vincristine (Vincristina, 1 mg mL-1, Pharmacia, Crinos, Milan, Italy) on 
day 8, oral 75 mg m-2 cyclophosphamide (Endoxan, 50 mg, Baxter, Milan, Italy) on 
days 15 through 18, and IV 30 mg m-2 doxorubicin (Adriblastina, 50 mg 25 ml, 
Pharmacia & Upjohn, Crinos, Milan, Italy) on day 22. Before administration of each 
dose, dogs were evaluated by physical examination and hematologic profile. After the 
completion of one cycle, dogs were restaged by means of physical examination, lymph 
node cytology, abdominal ultrasound, CBC, serum biochemistry profile and BM 
cytology. If dogs were in complete remission, after one-week interval the same cycle 
was repeated once more, by the end of which chemotherapy was stopped. Following 
completion of chemotherapy, dogs were rechecked monthly until relapse or death. 
Group 2 
Dogs included in Group 2 underwent the same treatment as that adopted for Group 1 
except for the incorporation of ara-C (Aracytin 500 mg 10 ml-1, Pfizer, Rome, Italy). 
For administration of ara-C, dogs were hospitalized. Briefly, after reconstitution, ara-C 
was diluted in 500 ml sodium chloride solution and administered as an IV continuous 
infusion at the dose of 150 mg m-2 per day for 5 consecutive days (days 1 through 5). To 
prevent severe myelosuppression and hasten the return of the neutrophil count, 
prophylactic 10 μg kg-1 subcutaneous granulocyte colony-stimulating factor (filgrastim, 
Neupogen 30 MU 1 ml, Dompè Biotec, Milan, Italy) was administered for 3 
consecutive days (days 4 through 6). In addition, to diminish the degree of anaemia and 
transfusion requirement, erythropoietin (Eprex 8000 UI 0.8 ml, Jannsen Cilag, Milan, 
Italy) was given subcutaneously at the dose of 150 UI kg-1 on day 4, 6 and 8. During 
hospitalization, empiric antibiotic prophylaxis including 25 mg kg-1 subcutaneous 
clavulanate-potentiated amoxicillin (Synulox 175 mg ml-1, Pfizer, Rome, Italy) once 
daily and 5 mg kg-1 IV enrofloxacin (Baytril 50 mg ml-1, Bayer, Milan, Italy) twice 
daily, was given. Standard antiemetic therapy consisted of subcutaneous 0.4 mg kg-1 
metoclopramide (Plasil 10 mg 2 ml-1, Lepetit, Milan, Italy) three times daily. In the case 
of severe vomiting, 0.15 mg kg-1 ondansetron (Zofran 8 mg 4 ml-1, Glaxo Smith Kline, 
Verona, Italy) was administered intravenously. At discharge, owners were instructed to 
continue oral antibiotics and antiemetic therapy for one week. 
CBC was checked on day 3, 4, 5, 8 and 22. After this first cycle of chemotherapy, dogs 
were re-staged. BM was re-evaluated and a second cycle with or without ara-C was 
administered, depending on presence or absence of BM involvement, respectively. Dogs 
were allowed to receive a maximum of 2 cycles of this protocol; if partial or complete 
remission was not achieved by the end of the second cycle, dogs were taken off the ara-
C trial and a rescue protocol was then offered. 
 
In either group, toxicity was assessed according the guidelines of the Veterinary Co-
Operative Oncology Group24. 
 
Evaluation of clinical response 
To evaluate response, every clinical, radiological, ultrasonographic, or laboratory 
investigation that disclosed abnormalities at pre-treatment staging was repeated at the 
end of two cycles of chemotherapy. Complete remission (CR) was defined as no clinical 
evidence of LSA, BM with active hematopoiesis and less than 5% lymphoid blast cells, 
normalization of peripheral counts with no detectable lymphoid blast cells on peripheral 
smears, and normal abdominal ultrasound. Partial remission (PR) was defined as 
reduction of marrow lymphoid blasts by more than or equal to 50% and to less than 
10%, blood count recovery with the persistence of few immature peripheral cells (<5%), 
reduction of hepato-splenomegaly as assessed by ultrasound performed by the same 
operator, and 50% or greater decrease in one dimension in all peripheral lymph nodes. 
Stable disease (SD) was defined as less than a 50% decrease in one dimension but no 
more than a 10% increase in any dimension of all measurable tumors, with marrow 
lymphoid blasts reduced by less than 50%. Progressive disease (PD) was defined as a 
10% or more increase in any dimension of measurable tumour with no reduced or 
increased marrow lymphoid blasts. Relapse was defined as clinical reappearance and 
cytological evidence of LSA in any anatomical site in dogs who have had CR, whereas 
relapse for animals with PR was defined as progression. 
 
Treatment of relapse 
Following relapse, patients were completely restaged. If patients relapsed at least 4 
months after cessation of chemotherapy, a re-induction of remission with the same 
protocol used before was tempted. Ara-C was added only if used before and in the case 
of marrow relapse. If the first remission lasted less than 4 months, the same protocol 
used before was initiated in both groups, unless there was evidence of BM involvement. 
In this last case, a rescue protocol was offered. 
 
 
STATISTICAL ANALYSIS 
In either group, gender, age and LSA immunophenotype were studied to verify a 
potential association with survival, using the Spearman correlation coefficient. 
Survival time was calculated from the date of first dose of chemotherapy to date of 
death. Survival curves were compared with the Kaplan-Meier method followed by the 
log-rank test. Cases were censored if lost to follow-up or if alive at the end of the study. 
CR, PR, SD and PD rates between Group 1 and Group 2 were compared by Fisher’s 
exact test. Significance was set at p < 0.05. 
 
 
RESULTS 
Patients and tumor characteristics 
Seventeen client-owned dogs with previously untreated LSA with BM involvement 
were enrolled. All dogs had cytologically confirmed high-grade LSA according to the 
updated Kiel’s classification25 and BM involvement (stage V); in addition all dogs were 
symptomatic at presentation (substage b). Acute lymphoblastic leukaemia was ruled out 
in all dogs by lack of CD34 expression. After diagnosis of LSA, all dogs underwent 
initial complete staging work-up. Overall, median age was 8 years (range, 3 to 18). Nine 
dogs (53%) were intact males and one (5.9%) was castrated; among the female dogs, 4 
(23.5%) were intact and 3 (17.6%) were spayed. Peripheral lymphadenopathy was 
present in 16 (94%) dogs, splenomegaly in 14 (82%) dogs, and hepatomegaly in 13 
(76%) animals. Circulating leukaemic cells were identified in all dogs; median WBC 
count was 320.000 cells/μl (range, 170.000 to 680.000), median haemoglobin level was 
9 g/dl (range, 6 to 11) and median platelet count was 49.000 platelets/μl (range, 12.000 
to 109.000). Examination of BM revealed infiltration of lymphoblasts in all cases, 
ranging from scattered aggregates to complete effacing of the normal hematopoietic 
architecture (32 to 98% of the total nucleated cells). 
When evaluated by immunophenotyping, 12 LSA were of B-cell origin and 5 were of 
T-cell origin. As regarding the B-cases, 8 (66.7%) were classified as centroblastic, 3 
(25%) as immunoblastic and 1 (8.3%) as lymphoblastic. Within the T-cell category, 3 
(60%) were classified as pleomorphic medium/large, whereas 2 (40%) were classified 
as immunoblastic. 
Clinical and pathological features of the treated dogs at disease onset are listed in Table 
1. 
 
Chemotherapy and related toxicity 
After the staging evaluation, and with a maximum delay after diagnostic procedures of 3 
days, the enrolled dogs received the first chemotherapeutic dose. Of the 17 dogs 
enrolled, 8 of these (47%) were treated with the modified VCAA protocol (Group 1), 
whereas in the remaining 9 dogs (53%) ara-C was incorporated (Group 2). All dogs 
were assessable for toxicity. 
Group 1 
With the exception of case 8 which received doxorubicin as first drug, all other dogs 
received the planned sequential study treatment. Case 1 completed the planned 2 cycles 
of VCAA and was treated with a rescue protocol thereafter. Case 2, 3, 4 and 8 did not 
complete the planned two cycles and were eventually euthanized because of worsening 
of their general conditions. The remaining cases completed the planned 2 cycles and did 
not receive any additional treatment. 
Side effects during chemotherapy were minimal. Grade 2 gastro-intestinal toxicity was 
recorded in 2 dogs, and one of these experienced grade 1 hematologic toxicity also. No 
documented side effects occurred in the remaining 6 dogs. 
Group 2 
All dogs completed the entire program (2 cycles of chemotherapy) with full drug doses 
and within the scheduled intervals. 
Treatment-related toxicity was mild and limited to gastro-intestinal and hematologic 
adverse events. One dog became inappetent after the second day of ara-C infusion, but 
was easily managed by dietary change. An additional dog experienced grade 2 vomiting 
after the first day of ara-C infusion, and required IV 0.15 mg/kg ondansetron twice daily 
for 3 days in addition to metoclopramide to recover. Grade 1 hematologic toxicity was 
recorded in 3 dogs during ara-C administration; however, there were no 
myelosuppression- associated complications and all dogs recovered uneventfully. 
Toxicity other than hematologic or gastrointestinal was not observed. Neither 
chemotherapy-related deaths nor tumor lysis syndrome occurred during the study. With 
the used protocol, adverse events did never result in treatment delays, dose reduction or 
hospitalisation following day 5.  
 
Clinical outcome 
All 17 dogs were assessable for the intent-to-treat analysis of tumor response. 
All dogs belonging to Group 1 had died for their disease at the end of the study, with a 
median survival time of 72.5 days (range, 6 to 174). Case 1 never obtained remission 
and chemotherapy was not interrupted. However, after 110 days the dog’s conditions 
deteriorated and the owner elected euthanasia. Case 2, 3 and 4 experienced PD during 
chemotherapy and were eventually euthanized after 37, 24 and 17 days, respectively. 
Case 5 obtained nodal CR, whereas permission to revaluate BM was denied, thus 
preventing accurate staging and precise evaluation of response. In this dog the response 
lasted for 174 days and at relapse euthanasia was elected by the owner. Case 6 obtained 
PR of 92 days duration; overall survival for this dog was 110 days. Case 7 obtained 
nodal CR but, again, owners did not allow revaluation of BM. Response lasted for 108 
days and at relapse owners elected euthanasia. Case 8 died 6 days after the first drug 
administration. Overall, there were 2 (25%) clinical CR, 1 (12.5%) PR, 1 (12.5%) SD 
and 4 (50%) PD. Response rates for Group 1 are shown in Table 2. 
With the exception of one case (case 14) which was alive with no evidence of disease, 8 
out of the 9 dogs included in Group 2 were dead at the end of the study as a result of 
their disease. Median survival for this group was 243 days (range, 73 to 635). The 
response of case 9 was defined as stable, however when the dog’s body conditions 
worsened, the owner elected euthanasia. Case 10, 11, 12 and 13 obtained CR of 165, 62, 
66 and 215 days duration, respectively. In either dog, LSA relapsed in the peripheral 
lymph nodes only and CR was re-induced by using the same protocol as the one 
previously adopted without the addition of ara-C. The second CR lasted for 201, 263, 
116 and 58 days, respectively; however, after marrow relapse all owners elected 
euthanasia. Overall survival for these dogs was 366, 325, 182 and 273 days, 
respectively. Case 14 obtained CR of 364 days duration. LSA relapsed in peripheral 
lymph nodes and spleen, and CR was re-induced by using the previously adopted 
protocol with the exclusion of ara-C. After 213 days, LSA relapsed in the peripheral 
lymph nodes only. The same protocol re-induced CR. At the time of writing the dog is 
still alive and in CR. CR was induced in case 15 and response was observed for 102 
days. After nodal relapse, CR was re-induced for 141 days with no further addition of 
ara-C. This dog was eventually euthanized after the second relapse; survival time was 
243 days. Case 16 and 17 obtained CR of 138 and 185 days duration; however, LSA 
relapsed in BM and the owners elected euthanasia. Overall, 8 dogs (88.9%) achieved 
CR after one cycle of chemotherapy, whereas one dog (11.1%) was defined as stable. 
All complete responders subsequently relapsed, and 6 of them received subsequent 
chemotherapy re-inducing CR, whereas 3 dogs were euthanized based on the owner’s 
wishes. Response rates for Group 2 are shown in Table 3. 
Regarding prognostic factors, age, gender and immunophenotype of LSA were not 
associated to survival in either group. Dogs which had ara-C included in the 
chemotherapeutic protocol had significantly longer survival than dogs without the 
nucleoside analogue (p < 0.001, ratio: 0.29, 95% CI: 0.00-0.67; Fig. 1). The rate of dogs 
which went into CR was higher in Group 2 (p < 0.01) and the rate of PD was higher in 
Group 1 (p < 0.05). The proportion of PR and SD was not different between groups. 
 
 
DISCUSSION 
In veterinary medicine, the treatment of canine LSA has not dramatically changed over 
the past 15 years, despite the use of poly-chemotherapeutic regimens and more accurate 
staging, including immunophenotyping.26 LSA involving the BM is infrequent in dogs, 
and is usually associated with poor prognosis.1-6 According to several published papers, 
the treatment of stage V LSA in dogs has met with much less success than in dogs with 
stage I-IV LSA, and long-term disease-free survival is unlikely.1-6 Due to the 
disappointing response to conventional chemotherapeutic regimens, the question 
whether to treat these cases still remains a matter of controversy. Furthermore, if the 
BM is myelophthysic, chemotherapy is often poorly tolerated and treatment results are 
scant. In the published literature, data on efficacious treatments for stage V canine LSA 
is lacking, and usually conventional protocols are applied. 
Ara-C is a nucleoside analogue8 that is considered one of the most active agents for the 
treatment of human acute leukaemias.9,10 The administration of ara-C in this study was 
hypothesized to increase remission rate in dogs which would otherwise have a poor 
prognosis. The postulate that ara-C may improve clinical response rates in dogs with 
stage V LSA was supported by the encouraging results observed in people affected by 
acute leukaemia. Therefore, in an attempt to induce a complete clinical and marrow 
remission, ara-C was incorporated to the traditional VCAA-based protocol and the 
results were compared with those of a control group of dogs who received the sole 
modified VCAA protocol. The choice of whether to administer ara-C was left to the 
owners and was mainly influenced by financial reasons. In fact, the use of ara-C in a 
myeloablative regimen needs to be accompanied to administration of colony-stimulating 
factors, which are expensive. Indeed, to minimize the risk of infection in the induction 
period, which is the unavoidable complication of aggressive, marrow ablative 
chemotherapy, supportive care including prophylactic parenteral antibiotics and colony-
stimulating factors were administered.27,28 In particular, growth-factor support allowed 
the use of this dose-intensive regimen at scheduled intervals with acceptable toxicity. 
Growth factors were administered after marrow-ablative chemotherapy was initiated 
because of concern that committed cells would be recruited and then exposed to 
cytotoxic drugs, thereby leaving fewer committed marrow progenitors for subsequent 
cycles. In this study, both G-CSF and erythropoietin improved neutropenia and anemia 
after intensive chemotherapy, thus ameliorating quality of life and preventing treatment 
related-deaths. Treatment was well tolerated; the most frequently experienced adverse 
events in this trial were gastrointestinal (2 dogs in both groups) and hematologic (1 dog 
in Group 1 and 3 dogs in Group 2). In either group, no dog died as a result of treatment-
related toxicity. We believe that the intensive ara-C-containing regimen did not lead to 
significant toxicity because of the protective effect of growth factors. However, the 
exact timing of administration of growth factors is not yet established and future clinical 
trials need to be focused on alternating schedules in order to better explore this issue. 
In this study, outcome was significant superior with incorporation of ara-C compared 
with the traditional regimen, in terms of both CR rate and survival time. In fact, in the 
overall study population, the incorporation of ara-C to traditional chemotherapeutic 
regimen led to significantly higher CR rates (88.9% versus 25%). Furthermore, survival 
time was also improved by the incorporation of ara-C (243 days versus 72.5 days). 
In general, canine high grade lymphomas of any clinical stage are assumed to be 
associated with a high initial response rate, followed by a clinical course characterized 
by a pattern of repeated relapses. Subsequent remission may occur, but typically at a 
lower rate and with a shorter duration, eventually leading to death or euthanasia of these 
patients.1,26 Of interest, in many dogs treated with ara-C in addition to the modified 
VCAA protocol, the second remission lasted longer than the first one, strongly 
suggesting that this strategy contributes additional antitumor activity, yielding 
beneficial long-term effects. Two dogs (cases 6 and 7) in Group 2 achieved clinical CR 
after one cycle of VCAA; however, BM was not evaluated after the completion of 
chemotherapy because of owners’ refusal and marrow remission could not be definitely 
demonstrated. 
In the current study, the analysis of prognostic factors suggested that some previously 
well-established poor prognostic factors such as some host characteristics (such as male 
gender and presence of symptoms) and disease characteristics (such as T-
immunophenotype and BM involvement)6,26,29 were less important with this marrow 
ablative protocol. One possible explanation is that improved therapy may have 
eliminated or minimized the effect of the pre-treatment variable. In fact, dogs with poor 
prognostic factors responded to the ara-C-containing regimen. Alternatively, the limited 
number of dogs included in each group may have biased the analysis, thus preventing 
the above factors to be associated with prognosis. 
Unfortunately, 8 out of the 9 ara-C-treated dogs still died from disease progression. 
Future investigations should focus on further improving the outcome in canine patients 
with stage V LSA. This may be accomplished by several approaches, including the use 
of new agents with selective or targeted effects, such as monoclonal antibodies23,30 or 
novel tyrosine kinase inhibitors,31,32 immuno-modulation,33,34 vaccines35,36 and 
autologous BM transplants,37 as well as discovering new chemotherapy agents. In the 
current study, chemotherapy was interrupted after the induction phase. The role of 
maintenance therapy in the treatment of this selected subset of patients should be 
investigated. Furthermore, monitoring the patients for minimal residual disease may 
result in early relapse detection and prompt treatment, ultimately leading to further 
outcome improvement. Randomized trials in which animals are enrolled under similar 
entrance criteria and randomly treated are needed; however, this has practical limitation, 
since canine LSA with BM involvement is quite infrequent and studies are rarely 
developed in cooperative efforts, unless investigators are truly convinced of the 
potential superiority of the proposed new protocol. 
In conclusion, this is the first study reporting the efficacy and safety of ara-C in 
combination with a conventional chemotherapeutic protocol in the treatment of canine 
LSA with BM infiltration. The clinical results reported here show a remarkable effect of 
ara-C-containing regimen on CR rate and overall survival. Furthermore, side effects 
were acceptable and never life-threatening, suggesting that the incorporation of ara-C to 
traditional poly-chemotherapeutic protocols is relatively safe if proper preventive 
countermeasures are adopted. However, the need for hospitalization during the marrow 
ablative therapy and the adjunctive use of growth factor support make this protocol 
more difficult to be performed and owner compliance may be the most important 
limiting factor to its use. 
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